

Teofila C Seremet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4210210/publications.pdf>

Version: 2024-02-01

26
papers

1,134
citations

516215

16
h-index

610482

24
g-index

27
all docs

27
docs citations

27
times ranked

2155
citing authors

#	ARTICLE	IF	CITATIONS
1	Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial. <i>Cancers</i> , 2022, 14, 682.	1.7	6
2	The predictive and prognostic significance of cell-free DNA concentration in melanoma. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 387-395.	1.3	17
3	Whole-Body MRI for the Detection of Recurrence in Melanoma Patients at High Risk of Relapse. <i>Cancers</i> , 2021, 13, 442.	1.7	7
4	A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. <i>Cancers</i> , 2021, 13, 168.	1.7	24
5	Pembrolizumab for the treatment of uveal melanoma: A case series. <i>Rare Tumors</i> , 2020, 12, 203636132097198.	0.3	8
6	A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 2589-2598.	2.0	44
7	Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases. <i>ESMO Open</i> , 2019, 4, e000464.	2.0	21
8	Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy. <i>Journal of Translational Medicine</i> , 2019, 17, 303.	1.8	89
9	Anaphylaxis-like reaction to anti-BRAF inhibitor dabrafenib confirmed by drug provocation test. <i>Melanoma Research</i> , 2019, 29, 95-98.	0.6	6
10	Phase 2 Trial of Nivolumab Combined With Stereotactic Body Radiation Therapy in Patients With Metastatic or Locally Advanced Inoperable Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 828-835.	0.4	46
11	Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. <i>Annals of Oncology</i> , 2019, 30, 1154-1161.	0.6	170
12	Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2019, 3, 1-10.	1.5	25
13	Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitor-refractory, advanced-stage melanoma. <i>Melanoma Research</i> , 2019, 29, 85-88.	0.6	15
14	Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy. <i>Melanoma Research</i> , 2018, 28, 65-70.	0.6	18
15	Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition. <i>Blood Advances</i> , 2018, 2, 2156-2158.	2.5	19
16	Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. <i>Lancet Oncology</i> , The, 2017, 18, 464-472.	5.1	139
17	Applications for quantitative measurement of BRAF V600 mutant cell-free tumor DNA in the plasma of patients with metastatic melanoma. <i>Melanoma Research</i> , 2016, 26, 157-163.	0.6	16
18	Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients. <i>Journal of Translational Medicine</i> , 2016, 14, 232.	1.8	27

#	ARTICLE	IF	CITATIONS
19	Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors. <i>Journal of Translational Medicine</i> , 2016, 14, 95.	1.8	117
20	Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib. <i>Melanoma Research</i> , 2015, 25, 550-554.	0.6	39
21	Objective responses can be obtained by CTLA-4 inhibition in metastatic melanoma after BRAF inhibitor failure. <i>Melanoma Research</i> , 2015, 25, 68-74.	0.6	11
22	Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma. <i>Melanoma Research</i> , 2015, 25, 180-183.	0.6	13
23	Neogenesis of Lymphoid Structures and Antibody Responses Occur in Human Melanoma Metastases. <i>Cancer Research</i> , 2012, 72, 3997-4007.	0.4	221
24	Tumor-Specific Antigens and Immunologic Adjuvants in Cancer Immunotherapy. <i>Cancer Journal (Sudbury, Mass)</i> , 2011, 17, 325-330.	1.0	36
25	Flavonoid And Low Level Long Wavelength Laser Irradiation Effects Seen In Human T Cells. <i>Biophysical Journal</i> , 2009, 96, 534a.	0.2	0
26	S8.14 Low power long wavelength laser irradiation effects on human mononuclear cell mitochondrial membrane potential. <i>Biochimica Et Biophysica Acta - Bioenergetics</i> , 2008, 1777, S51.	0.5	0